• Damora Therapeutics launched the Phase 1/1b CLARITY-101 trial of DMR-001 in mutant CALR-driven essential thrombocythemia, myelofibrosis.
• Initial trial results have not been presented; first data are expected from mid-2027.
• Study aims to assess safety, tolerability, early signs of benefit for a once-monthly subcutaneous antibody designed to block the disease driver.
• Development strategy targets patients who failed prior standard therapies, with a later expansion planned for earlier use, combination settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050800PRIMZONEFULLFEED9803970) on August 05, 2026, and is solely responsible for the information contained therein.